Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer
Abstract Hepatocellular carcinoma (HCC) is an aggressive malignancy without effective therapeutic approaches. Here, we evaluate the tumor-intrinsic mechanisms that attenuate the efficacy of immune checkpoint inhibitor (ICI) that is observed in patients with advanced HCC who progress on first-line ty...
Main Authors: | Yunong Xie, Haofeng Wu, Yimiao He, Linglin Liu, Ianto Bosheng Huang, Lei Zhou, Cheuk-Yin Lin, Rainbow Wing-Hei Leung, Jia-Jian Loh, Terence Kin-Wah Lee, Jin Ding, Kwan Man, Stephanie Ma, Man Tong |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-02-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-024-06493-0 |
Similar Items
-
Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma
by: Rainbow Wing Hei Leung, et al.
Published: (2022-11-01) -
Hampering Stromal Cells in the Tumor Microenvironment as a Therapeutic Strategy to Destem Cancer Stem Cells
by: Katherine Po Sin Chung, et al.
Published: (2021-06-01) -
The Receptor Tyrosine Kinase AXL in Cancer Progression
by: Erinn B. Rankin, et al.
Published: (2016-11-01) -
Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network
by: Xinyan Wu, et al.
Published: (2021-08-01) -
Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer
by: Man Tong, et al.
Published: (2021-11-01)